Medical Condition News

RSS

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

A new study by a University of Arkansas biomedical engineer and his colleagues at the National Cancer Institute demonstrates further promise for chitosan/interleukin-12 as an effective anti-tumor immunotherapy.

13 Oct 2010

Patients with memory impairment have intact ability to hold information in mind: Research

Researchers at the University of California, San Diego School of Medicine, led by Larry R. Squire, PhD, professor of psychiatry, psychology and neurosciences at UC San Diego and a scientist at the VA San Diego Healthcare System, report that working memory of relational information where an object is located, for example remains intact even if key brain structures like the hippocampus are damaged.

13 Oct 2010

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

The U.S. Food and Drug Administration's approval of Alkermes' opioid dependence medication (VIVITROL) for the prevention of relapse to opioid dependence following opioid detoxification is positive news for families of young adults and all those who are struggling to overcome opioid addiction. Addiction, a disease of the human brain, is a chronic illness while opioid dependence is frequently characterized by relapse.

13 Oct 2010

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.

13 Oct 2010

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

A combination of Biothera's Imprime PGG and cetuximab (Erbitux) doubled the overall response rates for second- and third-line metastatic colorectal cancer patients participating in a Phase Ib/IIa clinical trial. The completed trial results were released yesterday at the 35th European Society for Medical Oncology (ESMO) Congress.

13 Oct 2010

Genmab and Lundbeck enter agreement to develop antibody therapeutics

Genmab A/S announced today an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab's antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms.

13 Oct 2010

Threshold announces TH-302 Phase 1/2 clinical trial interim results

Threshold Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 1/2 clinical trial in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented at the European Society for Medical Oncology (ESMO) Annual Meeting being held in Milan, Italy.

13 Oct 2010

BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA

BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.

From Baxter International Inc. 13 Oct 2010

Archimedes publishes results from FPNS Phase III clinical study for breakthrough cancer pain

Archimedes Pharma, an emerging specialty pharma company focused on oncology, pain, neurology and critical care sectors, today announced publication of results from a Phase III, long-term safety, tolerability and consistency of effect, clinical study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTCP).

13 Oct 2010

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

Kennedy Krieger Institute announced today the launch of a first‐of‐its‐kind, phase II clinical trial to investigate a treatment for heart disease in individuals with Duchenne muscular dystrophy (DMD).

13 Oct 2010

New cancer initiative may promote rapid drug development

Greenville Hospital System University Medical Center (GHS) unveiled details of its new Institute for Translational Oncology Research, a visionary cancer initiative that will help pave the way for new breakthroughs in rapid drug development, diagnostic discovery and advanced cancer care. ITOR is part of the GHS Cancer Center, a recognized regional multi-disciplinary center.

13 Oct 2010

NCI rates Abramson Cancer Center as 'exceptional'

The University of Pennsylvania's Abramson Cancer Center has been rated as "exceptional" by the National Cancer Institute (NCI) during a competitive research funding review by the government agency.

13 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

Kuwait Healthy Life Study to examine metabolic health in children

In the face of a dramatic worldwide increase in adolescent obesity and Type 2 diabetes, The Forsyth Institute today announced a research alliance with the Dasman Diabetes Institute of Kuwait to initiate studies that could lay a scientific basis for prevention. This collaboration, called The Kuwait Healthy Life Study, will examine conditions in children that predispose them to obesity and Type 2 diabetes.

13 Oct 2010

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Oct 2010

NHC enter agreement with Attain to offer new program for IVF fertility treatments

IntegraMed America, Inc. the leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, today announced that its Attain Fertility Centers division has entered into an agreement with The New Hope Center for Reproductive Medicine (NHC) to begin offering the Attain IVF family of specialty financing Programs.

13 Oct 2010

Redesigned version of CTC-Chip effective in capturing rare circulating tumor cells

A redesigned version of the CTC-Chip a microchip-based device for capturing rare circulating tumor cells (CTCs) appears to be more effective and should be easier to manufacture than the original. Called the HB-(herringbone) Chip, the new device also may provide more comprehensive and easily accessible data from captured tumor cells.

13 Oct 2010

Immunomedics receives additional patent claims for antibody therapy

Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that additional claims for the patent family "Method and kit for imaging and treating organs and tissue," were issued as U.S. Patent No. 7,811,570.

13 Oct 2010

Researchers use brain imaging to differentiate pediatric bipolar disorder, ADHD

Researchers at the University of Illinois at Chicago are the first to use brain imaging to examine the effects of emotion on working memory function in children with pediatric bipolar disorder or attention deficit hyperactivity disorder.

13 Oct 2010

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Scientists have found that a synthetic molecule they designed can block activation of a gene in liver cancer cells, halting a process that allows some of those cancer cells to survive chemotherapy.

13 Oct 2010

Medical Condition News

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

Patients with memory impairment have intact ability to hold information in mind: Research

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

Genmab and Lundbeck enter agreement to develop antibody therapeutics

Threshold announces TH-302 Phase 1/2 clinical trial interim results

BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA

Archimedes publishes results from FPNS Phase III clinical study for breakthrough cancer pain

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

New cancer initiative may promote rapid drug development

NCI rates Abramson Cancer Center as 'exceptional'

New evidence supports possible link between XMRV and prostate cancer

Kuwait Healthy Life Study to examine metabolic health in children

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

NHC enter agreement with Attain to offer new program for IVF fertility treatments

Redesigned version of CTC-Chip effective in capturing rare circulating tumor cells

Immunomedics receives additional patent claims for antibody therapy

Researchers use brain imaging to differentiate pediatric bipolar disorder, ADHD

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News